Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 246

Similar articles for PubMed (Select 22820987)

1.

BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.

Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.

Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.

PMID:
22820987
3.

Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways.

Heublein S, Mayr D, Meindl A, Angele M, Gallwas J, Jeschke U, Ditsch N.

PLoS One. 2015 Jun 1;10(6):e0127072. doi: 10.1371/journal.pone.0127072. eCollection 2015.

4.

Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.

Shenker NS, Flower KJ, Wilhelm-Benartzi CS, Dai W, Bell E, Gore E, El Bahrawy M, Weaver G, Brown R, Flanagan JM.

BMC Cancer. 2015 May 1;15:337. doi: 10.1186/s12885-015-1335-5.

5.

BRCA1 germline mutation and glioblastoma development: report of cases.

Boukerroucha M, Josse C, Segers K, El-Guendi S, Frères P, Jerusalem G, Bours V.

BMC Cancer. 2015 Mar 26;15:181. doi: 10.1186/s12885-015-1205-1.

6.

Discordant pattern of BRCA1 gene epimutation in blood between mothers and daughters.

Wojdacz TK, Harari F, Vahter M, Broberg K.

J Clin Pathol. 2015 Jul;68(7):575-7. doi: 10.1136/jclinpath-2015-202982. Epub 2015 Apr 15.

PMID:
25878326
7.

Decreased BECN1 mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis.

Tang H, Sebti S, Titone R, Zhou Y, Isidoro C, Ross TS, Hibshoosh H, Xiao G, Packer M, Xie Y, Levine B.

EBioMedicine. 2015 Mar;2(3):255-263.

8.

Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer.

Li Q, Wei W, Jiang YI, Yang H, Liu J.

Oncol Lett. 2015 Apr;9(4):1807-1813. Epub 2015 Jan 27.

9.

Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.

Zhu X, Shan L, Wang F, Wang J, Wang F, Shen G, Liu X, Wang B, Yuan Y, Ying J, Yang H.

Breast Cancer Res Treat. 2015 Apr;150(3):479-86. doi: 10.1007/s10549-015-3338-y. Epub 2015 Mar 18.

PMID:
25783183
10.

Linking BRCA1 to NAD World.

Wang XX, Li D.

Cell Cycle. 2015;14(7):941-2. doi: 10.1080/15384101.2015.1006542. No abstract available.

PMID:
25713994
11.

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.

Aleskandarany M, Caracappa D, Nolan CC, Macmillan RD, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2015 Feb;150(1):81-90. doi: 10.1007/s10549-015-3306-6. Epub 2015 Feb 19.

12.

Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

Jacot W, Theillet C, Guiu S, Lamy PJ.

Future Oncol. 2015 Feb;11(4):557-9. doi: 10.2217/fon.14.268. No abstract available.

PMID:
25686112
13.

LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.

Nagasawa S, Sedukhina AS, Nakagawa Y, Maeda I, Kubota M, Ohnuma S, Tsugawa K, Ohta T, Roche-Molina M, Bernal JA, Narváez AJ, Jeyasekharan AD, Sato K.

PLoS One. 2015 Feb 13;10(2):e0118002. doi: 10.1371/journal.pone.0118002. eCollection 2015.

14.

Clinicopathological significance of BRCA1 promoter hypermethylation in Thai breast cancer patients.

Saelee P, Chaiwerawattana A, Ogawa K, Cho YM, Tiwawech D, Suktangman V.

Asian Pac J Cancer Prev. 2014;15(24):10585-9.

15.

FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer.

Gong C, Fujino K, Monteiro LJ, Gomes AR, Drost R, Davidson-Smith H, Takeda S, Khoo US, Jonkers J, Sproul D, Lam EW.

Oncogene. 2014 Dec 22. doi: 10.1038/onc.2014.421. [Epub ahead of print]

PMID:
25531315
16.

Biological and clinical significance of PARP1 protein expression in breast cancer.

Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.

17.

Hormone responsive breast cancer and BRCA1 mutation: mechanism, regulation and iron-mediated effects.

Zghair AN, Sharma R, Sharma AK.

Curr Pharm Biotechnol. 2014;15(12):1113-24.

PMID:
25429655
18.

Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.

Gupta S, Jaworska-Bieniek K, Narod SA, Lubinski J, Wojdacz TK, Jakubowska A.

Breast Cancer Res Treat. 2014 Dec;148(3):615-22. doi: 10.1007/s10549-014-3179-0. Epub 2014 Nov 7.

PMID:
25376744
19.

[Progress in the effects of BRAP gene on cardiovascular diseases].

Lv D, Zhu YM.

Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 Sep;43(5):602-6. Chinese.

PMID:
25372649
20.

BRCA1 as target for breast cancer prevention and therapy.

Romagnolo AP, Romagnolo DF, Selmin OI.

Anticancer Agents Med Chem. 2014;15(1):4-14.

PMID:
25329591
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk